Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CHU Croix Rousse-Lyon

Verified siteinfo

France 103 Grande Rue De La Croix Rousse, 69317 Lyon, France

  • 48 trials recruiting
  • Metabolic dysfunction-associated steatohepatitis · Asthma · Hepatocellular carcinoma
  • Adults and children

About Specializations

CHU Croix Rousse-Lyon in Lyon, France specialises in clinical trials of conditions such as Metabolic dysfunction-associated steatohepatitis, Asthma, Hepatocellular carcinoma, Chronic obstructive pulmonary disease, and other specialisations. This site conducts important research.

Main research areas of the site

Otorhinolaryngology

The medical center is at the forefront of research in ear, nose, and throat diseases, focusing on innovative treatments and improving patient outcomes. The center's commitment to advancing the field is evident through its exploration of novel therapeutic approaches.

  • Idiopathic Purulent Oedematous Sinusitis
  • Quality of Life Improvements
  • Extended Antibiotic Therapies

By conducting multicenter randomized controlled trials, the center contributes significantly to the understanding and management of complex ENT conditions, enhancing the quality of life for patients through targeted interventions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
103 Grande Rue De La Croix Rousse69317 LyonFrance
Open in maps ↗
Recruiting now
48 trials
Conditions studied
92
Partner status
Verified site

More sites in LyonFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

116 clinical trials

Chronic obstructive pulmonary disease

Recruiting

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer

Metabolic dysfunction-associated liver disease

Recruiting

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Hepatic fibrosis+2

Recruiting

Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Chronic obstructive pulmonary disease

Recruiting

Study of Brenipatide (LY3537031) in Adults with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY3537031
  • Sponsor:Eli Lilly & Co.

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Colorectal cancer stage III

Recruiting

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.